Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals reported results from its 2026 annual stockholder meeting. A total of 59,742,819 shares of common stock were represented, about 74.65% of shares outstanding as of the April 24, 2026 record date, indicating strong participation.
Stockholders elected three Class III directors—Jerome Adams, MD, MPH, Howard Berman, PhD, and Barbara Duncan—to serve until the 2029 annual meeting and until their successors are elected and qualified. They also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the executive compensation program for the company’s named executive officers.
Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock on May 18, 2026 at a weighted average price of $4.1715 per share. Following this trade, she directly owns 92,145 shares of Atea Pharmaceuticals.
The shares were bought in multiple transactions at prices ranging from $4.14 to $4.19 per share. This Form 4/A amends a prior Form 4 only to correct the transaction date, which had been mistakenly reported as May 18, 2025 instead of May 18, 2026.
Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock. The shares were bought on May 18, 2025 at a weighted average price of $4.1715 per share, with individual trade prices ranging from $4.14 to $4.19 per share. Following this transaction, Murphy directly holds 92,145 shares of Atea Pharmaceuticals common stock.
Atea Pharmaceuticals reported a Q1 2026 net loss of $45.4 million, compared with $34.3 million a year earlier, as it increased investment in late-stage antiviral programs.
Research and development expenses rose to $41.1 million, driven mainly by Phase 3 hepatitis C trials and hepatitis E preclinical work, while general and administrative costs declined to $6.9 million as the company managed overhead and stock-based compensation.
Atea ended March 31, 2026 with $256.0 million in cash, cash equivalents and marketable securities and expects this to fund operations through 2027 while it completes its global HCV Phase 3 program, advances AT-587 into a planned Phase 1 HEV study, and maintains an unused $200.0 million at-the-market stock offering facility.
Atea Pharmaceuticals reported a wider net loss for the first quarter of 2026 as it increased investment in its late-stage antiviral pipeline. Net loss was $45.4 million, or $(0.57) per share, compared with $34.3 million, or $(0.40) per share, a year earlier.
Research and development spending rose to $41.1 million, mainly to fund Phase 3 HCV trials and HEV preclinical work, while general and administrative expenses declined to $6.9 million. Atea ended March 31, 2026 with $256.0 million in cash, cash equivalents and marketable securities.
The company highlighted progress in its hepatitis C program, with Phase 3 C-BEYOND topline results expected in mid-2026 and C-FORWARD results around year-end 2026. It also plans to start a Phase 1 trial of HEV candidate AT-587 in mid-2026.
ATEA PHARMACEUTICALS INC reports that FMR LLC beneficially owned 11,950,771.87 shares of Common Stock, representing 15.0% of the class as of 03/31/2026.
The filing shows FMR LLC has sole dispositive power over 11,950,771.87 shares and sole voting power reported as 11,949,098. The disclosure notes that Fidelity Growth Company Commingled Pool held 6,535,486 shares (8.2%) as of 03/31/2026. The amendment is signed by an authorized representative under a power of attorney.
Atea Pharmaceuticals is asking stockholders to approve three main items at its 2026 virtual annual meeting: electing three Class III directors until 2029, ratifying KPMG as auditor for 2026, and an advisory vote on executive pay. Holders of common stock at the April 24, 2026 record date may vote.
The proxy also highlights business progress. Atea is advancing a Phase 3 regimen of bemnifosbuvir and ruzasvir for chronic hepatitis C, with topline data from the C‑BEYOND trial expected mid‑2026 and C‑FORWARD by year‑end 2026. Earlier Phase 2 data showed a 98% sustained virologic response 12 weeks after treatment among adherent patients.
Management reports a roughly 25% workforce reduction in early 2025, projected to save about $15 million through 2027, and completion of a $25 million stock repurchase program that retired 7,673,792 shares. The board emphasizes a classified structure, majority‑independent membership, and a pay‑for‑performance executive compensation program with most CEO target pay at risk and more than half of 2025 equity value in performance stock units.
Atea Pharmaceuticals Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of Common Stock following an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those subsidiary-held securities.
Atea Pharmaceuticals, Inc. officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at an exercise price of $1.2400 per share. The option was fully vested and exercisable. Following the transaction, she directly holds 823,576 shares of Atea common stock.
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing novel oral antivirals for serious viral diseases. Its lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV), positioned as a short-duration, pan‑genotypic, protease inhibitor‑free regimen.
Atea is running two large global Phase 3 trials, C‑BEYOND in the US/Canada and C‑FORWARD outside North America, each targeting about 880 treatment‑naïve HCV patients with and without compensated cirrhosis. C‑BEYOND is fully enrolled, with topline results expected mid‑2026, and C‑FORWARD topline data targeted for year‑end 2026, followed by a planned US NDA submission in March 2027.
The company is also advancing AT‑587, a nucleotide prodrug for chronic hepatitis E virus (HEV), with a first‑in‑human Phase 1 study planned for mid‑2026. Atea licenses ruzasvir from Merck under a global agreement that included a $25.0 million upfront payment, up to $135.0 million in development and regulatory milestones, up to $300.0 million in sales milestones, and tiered royalties from high single‑digit to mid‑teens percentages. Atea previously discontinued development of bemnifosbuvir for COVID‑19 after the Phase 3 SUNRISE‑3 trial did not meet its primary endpoint.